BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

/PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent...

Related Keywords

China , Yong Jiang , Zhejiang , Prnewswire Biocity Biopharma , Biocity Biopharma , , City Biopharma , Yong Jiang Hei ,